Back to Research Hub
ADMA Biologics, Inc.
ADMA
$8.12+0.06 (+0.74%)
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
StreetsValue research for ADMA Biologics, Inc. (ADMA)
Members get the full report for ADMA Biologics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.